CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More
New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer. Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Misetionamide’s inhibition… Read More
The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More
In a new study of non-statin cholesterol-lowering medications, cholesterol absorption inhibitors were linked to lower risks of liver cancer. Cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega-3 fatty acids are types of non-statin cholesterol-lowering medications prescribed to manage cholesterol and lipid levels. The different… Read More
A new study has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC), providing unique understanding of its response to treatment. The research was led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the… Read More
The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More
Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. The research was led by Senior Researcher Dr Vanessa Conn and Professor Simon Conn, who leads… Read More
Six teams have been accepted onto Phase II of the Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation. Selected from the 25 teams that took part in Phase I, three of the Phase II project teams will… Read More
Researchers at Guy’s and St Thomas’, and King’s College London in the UK have found that a bacteria is toxic for head and neck cancer and could lead to better treatments for patients. Fusobacterium is usually associated with the progression of bowel cancer. However, new research… Read More
Scientists have discovered that some cancer cells pretend to be ‘super fit’ to fool normal healthy cells into giving them their nutrients, allowing them to expand and spread around the body. A team from The Institute of Cancer Research (ICR), London, found that ‘cheating’ cancer cells… Read More
Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More
UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More
Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More
Keir Loiacono, CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals. The first is… Read More
CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon… Read More
The American Association of Cancer Research (AACR) Annual Meeting took place from 5-10 April 2024 in San Diego. DDW’s Megan Thomas spoke with Dr Paul Moore, Chief Scientific Officer at Zymeworks and Dr Nina Weisser, Director of Multispecific Antibody Therapeutics at Zymeworks, about the event as well as the future… Read More
